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Predictors for Identifying the Efficacy
of Systemic Steroids on Sustained
Exhaled Nitric Oxide Elevation
in Severe Asthma
Kazuto Matsunaga1, Tsunahiko Hirano1, Keiichiro Akamatsu1 and Yoshiaki Minakata1
ABSTRACT
Background: Some patients with asthma have high levels of exhaled nitric oxide fraction (FENO) despite in-
haled corticosteroids (ICS) therapy. Early studies suggested that this might be explained by the presence of
heterogeneous airway inflammation. We aimed to assess the predictors for identifying the efficacy of systemic
corticosteroids on residual FENO elevations in severe asthma.
Methods: Twenty severe asthmatics with persistent FENO elevation (40 ppb) despite maintenance therapy
including high-daily-dose ICS were enrolled. Asthma Control Questionnaire (ACQ), lung function, blood eosino-
phils, and FENO were assessed before and after 14 days treatment with 0.5 mgkg oral prednisoloneday.
Results: ACQ, blood eosinophils, FENO level, FVC, FEV1, FEV1FVC ratio and the slope of the single nitrogen
washout curve (ΔN2) were significantly improved by treatment with prednisolone. 70% of the subjects showed
20% reductions in the FENO levels. The reduction in FENO levels was significantly correlated with the improve-
ments in ACQ (p < 0.0001), FVC (p < 0.01), FEV1 (p < 0.0001), and ΔN2 (p < 0.05). Among the measurements
at baseline, the FENO levels and blood eosinophil numbers were identified as significant predictors of20% re-
ductions in the FENO levels by systemic steroid therapy.
Conclusions: Systemic corticosteroids could suppress the residual FENO elevations in more than half of the
patients with severe asthma and the reduction in FENO levels was associated with improvements in asthma
control and airflow limitation. The FENO levels and blood eosinophil numbers were the predictors of improved
residual airway inflammation by systemic steroid therapy in severe asthma.
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ABBREVIATIONS
ACQ, Asthma Control Questionnaire; DLCO, Diffusion capacity of the lung for carbon monoxide; dN2, Third
phase slope of the single nitrogen washout curve; FENO, Exhaled nitric oxide fraction.
INTRODUCTION
Asthma is an inflammatory disorder of the airways,
and inhaled corticosteroids (ICS) are widely used for
the long-term management of the disease.1 The ex-
haled nitric oxide fraction (FENO) is a useful surro-
gate marker to assess airway inflammation.2 The
FENO levels are elevated in steroid-naive asthma3 and
are generally reduced in a dose-dependent manner
by treatment with ICS.4 However, not all asthma pa-
tients respond to corticosteroids similarly and there
is considerable variation in the FENO levels.5 Indeed,
the FENO remains persistently high despite ICS ther-
apy in some individuals.6-10
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Table　1　Demographics of study subjects at baseline
Number (male/female) 20 (10/10)
Age (years) 53.5 ± 12.1
Body mass index (kg/mm2) 22.8 ± 3.9
Smoking status (never/ex) 9/11
Smoking index (pack-years) 16.6 ± 3.6
Atopy, n (%) 18 (90.0)
Serum total immunoglobulin E (IU/mL)  780 ± 951
Allergic rhinitis, n (%) 17 (85.0)
Chronic rhinosinusitis, n (%)  6 (30.0)
FVC (L) 3.16 ± 0.98
FVC % of predicted (%) 87.7 ± 9.8
FEV1 (L) 2.01 ± 0.76
FEV1/FVC ratio (%) 63.2 ± 13.9
FEV1 % of predicted (%) 66.2 ± 13.5
Inhaled corticosteroids, n (%) 20 (100.0)
Dose of inhaled corticosteroids (μg/day)† 1760 ± 228
Inhaled long-acting β2-agonist, n (%) 20 (100.0)
Leukotriene receptor antagonist, n (%) 13 (65.0)
Theophylline, n (%) 11 (55.0)
Values are Means ± SD. †Inhaled corticosteroids, expressed as 
beclomethasone dipropionate equivalent.
Fig.　1　Study design.
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A common cause of persistently high levels of
FENO is poor adherence to ICS therapy. Other expla-
nations could be poor inhaler technique, inadequate
dose of ICS, or persistent exposure to allergen.2 Sus-
tained high FENO may occur even in subjects without
respiratory symptoms.2 However, recent studies have
shown that the grouping of asthma by FENO provides
an independent classification of asthma severity, and
the subgroups with sustained high FENO tend to be a
highly reactive asthma phenotype.9,10 There is also
evidence that airway hyperresponsiveness as well as
high levels of FENO are related to exacerbations of
asthma and accelerated decline in lung function.11-14
Moreover, excessive nitric oxide (NO) synthesis was
found in individuals with refractory asthma.15 These
data might be explained by the presence of heteroge-
neous airway inflammation that is resistant to ICS
therapy.10,15-18 Among patients with refractory
asthma, it is speculated that some proportion of indi-
viduals are truly steroid resistant, which is defined as
no clinical improvement after treatment with sys-
temic corticosteroids.18 However, the predictors that
can stratify patients who can be expected to show im-
proved persistently high levels of FENO by treatment
with systemic steroids have not been fully elucidated
in severe asthma.
In the present study, severe asthma patients with
persistently high levels of FENO (40 ppb) despite
maintenance therapy including high-daily-dose ICS
were enrolled. We assessed the response to high-
dose systemic corticosteroids in terms of asthma con-
trol, lung function, blood eosinophils, and FENO level.
The potential of objective measurements made at
baseline for predicting the efficacy of systemic ster-
oids on residual airway inflammation was analyzed.
METHODS
STUDY SUBJECTS
Subjects over 20 years old were considered eligible if
they satisfied the standard criteria for asthma.19 All
subjects were recruited from June 2012 to August
2012. The criterion for refractory asthma from the
American Thoracic Society was used to determine
the severity classifications.20 The definition of severe
asthma required a combination of 1 of 2 major (oral
steroids for 50% of year, high-dose ICS) and 2 of 7
minor criteria (daily second controller medication,
near-daily basis short-acting β2-agonist use, persistent
airflow limitation, 1 urgent care visityear, 3 oral
steroids burstyear, deterioration with reduced ster-
oids, near-fetal event in the past). Subjects were ex-
cluded if they were current smokers, had had an ex-
acerbation of asthma or had been treated with sys-
temic steroids 8 weeks prior to the study. Also, pa-
tients with poor adherence to the treatment (defined
<80% adherence based on prescription refill data) or
with other pulmonary diseases were excluded. Com-
plete blood cell count, differential count of leuko-
cytes, total immunoglobulin E (IgE), and specific IgE
for common inhaled allergens were examined. Posi-
tive specific IgE to at least one allergen was assumed
to confirm the presence of atopy. All ex-smokers had
chest computed tomography to exclude clinically oc-
cult emphysema. This trial was approved by the local
Steroid Trial on Persistently High FENO
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Table　2　Changes in lung function, asthma control, blood eosinophils, and FENO levels during the study period
Characteristics
Screening
period
(-8 weeks)
Pre-steroid
treatment
(Baseline)
Post-steroid
treatment
(2 weeks)
p value
-8 weeks vs. 
baseline
p value
baseline vs.
2 weeks
FVC (L) 3.18 ± 0.98  3.16 ± 0.98  3.36 ± 0.89 0.42 <0.01
FEV1 (L) 1.99 ± 0.81  2.01 ± 0.76  2.25 ± 0.73 0.34 <0.01
FEV1/FVC ratio (%) 62.2 ± 14.7  63.2 ± 13.9  66.8 ± 13.8 0.31 <0.01
ΔN2 (%) -  2.2 ± 1.1  1.4 ± 0.7 - <0.01
DLCO/VA (%) - 105.4 ± 15.7 103.3 ± 12.7 - 0.44
ACQ (points) 1.9 ± 0.7  1.8 ± 0.6  1.1 ± 0.6 0.54 <0.01
Blood eos (cells/μL) 593 ± 278  561 ± 310  153 ± 158 0.61 <0.01
FENO (ppb) 63.2 ± 19.4  60.1 ± 21.3  38.0 ± 16.3 0.23 <0.01
Abbreviations: ΔN2, the third phase slope of the single nitrogen washout curve; DLCO, diffusion lung carbon monoxide; VA, alveolar vol-
ume; eos, eosinophils; ACQ, Asthma Control Questionnaire; FENO, exhaled nitric oxide fraction. Values are Means ± SD. Wilcoxon signed 
rank test p values are reported to compare the groups.
ethics committee (IRB #526) and registered with the
University hospital Medical Information Network
(UMIN 000008401). Informed written consent was
obtained from each participant.
STUDY DESIGN
This prospective observational study evaluated the re-
sponse to oral prednisolone in terms of asthma con-
trol, lung function, blood eosinophils, and airway
inflammation (Fig. 1). During the screening period,
FENO was measured before and after 8 weeks obser-
vation, and severe asthmatic patients with sustained
high levels of FENO (40 ppb) were enrolled. We em-
ployed Asthma Control Questionnaire (ACQ), lung
function test, blood sampling, and FENO measure-
ment before and after 14 days treatment with 0.5 mg
kg oral prednisolone・day−1. Asthma maintenance
treatment was continued without any changes during
the study period.
ASTHMA CONTROL QUESTIONNAIRE (ACQ),
LUNG FUNCTION, AND EXHALED NO
FENO was measured by a chemiluminescence ana-
lyzer (modified NA-623NⓇ; Chest, Tokyo, Japan) as
previously described.21 It has been confirmed that
the FENO values measured by this device is in agree-
ment with those of a widely used electrochemical
analyzer (NIOX MINO; Aerocrine, Solna, Sweden).22
Based on our study,10 we selected 40 ppb as the cut-
off point for high and low FENO, a value that was
within previously published cutoff points ranging
from 35 to 50 ppb.2,9,23 The forced vital capacity
(FVC), forced expiratory volume in 1 s (FEV1), the
third phase slope of the single nitrogen washout
curve (ΔN2), and diffusion lung carbon monoxide
(DLCO) were measured using a dry rolling seal spi-
rometer (CHESTAC-8800; Chest).21 The changes in
each variable were estimated according to the follow-
ing criteria: difference in ACQ score; percentage
changes in FVC, FEV1, ΔN2, and FENO (post-steroid
level - pre-steroid levelpre-steroid level × 100). Ster-
oid responsiveness of airway inflammation was de-
fined as 20% reduction in the FENO levels.2 The
ACQ-5 is a questionnaire that assesses the asthma
control according to five items, each of which can be
rated on a seven point scale.24 The overall score was
the mean of the five responses. This questionnaire
has been used in earlier studies in Japan.25
STATISTICAL ANALYSIS
All data were expressed as mean values ± standard
deviation. The measurements at different time points
were compared by Wilcoxon signed rank test. Spear-
man’s correlation analysis was performed to assess
the correlation. Receiver operating characteristic
curves were plotted to estimate the predictive value
of the baseline measurements for assessing the re-
sponse to oral steroids of airway inflammation. A p-
value of <0.05 was considered significant.
RESULTS
The baseline characteristics are listed in Table 1, 2. A
total of 20 patients with severe asthma completed the
study. Despite treatment with high-daily-dose ICS
(mean equivalent dose of 1,760 μg beclomethasone
dipropionateday), all study subjects were using sec-
ond controller medications, and the mean ACQ score
was 1.8. These characteristics were consistent with
the criteria for severe asthma. In addition, there was
no significant difference in ACQ score, lung function,
and the FENO levels between the screening period (-8
weeks) and the beginning of the treatment period
(baseline) (Table 2).
As shown in Table 2, oral steroids significantly re-
duced the FENO level from 60.1 ppb at baseline to
38.0 ppb at day 14 (p < 0.01). 14 of the subjects (70%)
showed 20% reduction in FENO levels (60% of the
subjects showed reductions in FENO of <40 ppb). Sig-
nificant improvements in ACQ score, FVC, FEV1,
FEV1FVC, ratio, ΔN2, and blood eosinophil numbers
Matsunaga K et al.
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Table　3　Receiver operator characteristic analysis for as-
sessing the predictors of ≥20% reduction in FENO levels by
the treatment with systemic corticosteroids
Predictors AUC Cutoffvalue
Sensi-
tivity
Speci-
fi city
ACQ 0.61   1.4 0.50 0.80
FVC % of predicted (%) 0.62  80.3 0.52 0.80
FEV1 % of predicted (%) 0.57  72.3 0.64 0.60
ΔN2 (%) 0.65   1.5 0.70 0.64
FENO (ppb) 0.71  49.7 0.76 0.73
Blood eosinophils (cells/μL) 0.72 416 0.79 0.72
Abbreviations: AUC, area under the curve; ACQ, Asthma Con-
trol Questionnaire; ΔN2, the third phase slope of the single nitrogen 
washout curve; FENO, exhaled nitric oxide fraction.
Fig.　2　Relationship between changes in exhaled nitric oxide fraction (FENO) and (A) dif-
ference in ACQ score, (B) percentage increase in FVC, (C) percentage increase in FEV1, 
(D) percentage reduction in third phase slope of the single nitrogen washout curve (dN2): 
The line corresponds to the fi tted regression equation. The r value is Spearman’s correla-
tion coefficient.
r = 0.78
p < 0.0001
r = -0.55
p < 0.01
0
-20
-40
-60
-80
F
E
N
O
 r
ed
uc
tio
n 
%
-2.0 -1.5 -1.0
Difference in ACQ
A
0
-20
-40
-60
-80
B
-0.5 0.0 -10 0 10 20
FVC increase %
30 40
r = -0.75
p < 0.0001
r = 0.45
p < 0.05
0
-20
-40
-60
-80
F
E
N
O
 r
ed
uc
tio
n 
%
0 20 40
FEV1 increase %
C
0
-20
-40
-60
-80
D
60 80 -80 -60 -40 -20
dN2 reduction %
0
were also found (all p < 0.01). Furthermore, the re-
ductions in the FENO levels were significantly corre-
lated with the improvements in ACQ (p < 0.0001),
FVC (p < 0.01), FEV1 (p < 0.0001), and ΔN2 (p < 0.05)
(Fig. 2), and showed a tendency to associate with the
reduction in blood eosinophils (p = 0.08).
In order to explore whether objective measure-
ments made at baseline might predict the responsive-
ness to oral steroids of airway inflammation, receiver
operating curve analyses were carried out. An area
under the curve of >0.7 was considered significant. As
shown in Table 3, the FENO levels and blood eosino-
phil numbers were identified as predictors of20% re-
duction in FENO levels by the treatment with oral
steroids (AUC = 0.71, and 0.72, respectively). The val-
ues of sensitivity and specificity for selected cutoff
values are also listed in Table 3. Indeed, both the
blood eosinophil numbers and the FENO levels at
baseline were negatively correlated with the changes
in FENO levels by systemic steroid therapy (r = -0.51,
p < 0.05, and r = -0.50, p < 0.05, respectively) (Fig. 3).
Steroid Trial on Persistently High FENO
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Fig.　3　Relationship between baseline (A) blood eosinophil numbers (B) exhaled nitric 
oxide fraction (FENO) and changes in FENO levels. The line corresponds to the fi tted re-
gression equation. The r value is Spearman’s correlation coefficient.
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DISCUSSION
In this prospective observational study of severe asth-
matics with sustained high levels of FENO, we found
that the ACQ, FVC, FEV1, FEV1FVC ratio, ΔN2,
blood eosinophils, and FENO were significantly im-
proved by systemic steroid therapy and the reduc-
tions in the FENO levels were related to the improve-
ments in ACQ, FVC, FEV1, and ΔN2. The FENO levels
and blood eosinophil counts at baseline were identi-
fied as useful predictors of improvement in airway in-
flammation by treatment with systemic corticoster-
oids.
High levels of FENO are known to represent signifi-
cant airway eosinophilia, and it is also likely to indi-
cate that a symptomatic patient has steroid-
responsive airway inflammation.2 However, in some
individuals, the FENO levels remain persistently high
despite adequate anti-inflammatory treatment.6-10 Re-
cent studies compared asthmatic subjects classified
as having high-FENO with subjects having low-FENO
and identified the common characteristics of this phe-
notype.9,10 Asthma patients with high FENO were
atopic and had more eosinophilic airway inflamma-
tion, more airway reactivity, more hyperinflation, and
the most frequent use of emergency care.9 Also, the
subjects with high-FENO were characterized by lower
FEV1 values, exaggerated fluctuation of airway cali-
ber, and more severe asthma symptoms.10 Previous
studies suggested that asthma patients with sus-
tained high FENO may have a vulnerable airway con-
dition that is resistant to corticosteroid.9,10 Indeed,
neutrophilic or persistent eosinophilic inflammation
was found in asthmatics with high FENO despite ster-
oid therapy.15-18 Interestingly, our study showed that
further anti-inflammatory therapy could suppress the
residual FENO elevations in more than half of the pa-
tients with severe asthma, and the reduction in the
FENO levels was related to improvements in asthma
control and airflow limitation. Our data supports a
prior study that showed persistent sputum eosino-
philia in patients with severe asthma is not a refrac-
tory phenomenon, but is still sensitive to systemic
corticosteroids.17 By contrast, in the present study,
30% of the subjects continued to show high levels of
FENO even after the systemic steroid trial, suggesting
that truly steroid resistant inflammatory processes in
the airway might also exist among some severe asth-
matic patients with sustained high levels of FENO.18
Predicting the responsiveness to anti-inflammatory
treatment on residual airway inflammation is impor-
tant in patients with severe asthma. As expected, the
baseline FENO level was associated with the improve-
ment in sustained airway inflammation by systemic
steroids. This may be related to the fact that FENO is
a useful marker of eosinophilic airway inflammation
even in patients on ICS therapy,2 thus show a greater
capacity to respond to additive systemic steroid ther-
apy. We speculated that small airways might be in-
volved in the residual airway inflammation because
the steroid-mediated reduction in the FENO levels
was correlated with the changes in ΔN2 values, which
reflect airway obstruction in the small airways.21
Also, the blood eosinophil number was the useful
predictor for identifying the subjects whose sustained
high levels of FENO responded to oral steroids. This
finding is novel and interesting given that blood
eosinophils play a critical role in pathophysiology of
severe asthma. Indeed, an increase in blood eosino-
phils was found in treated asthmatics and positive
correlations were found between the blood eosinophil
count and the FENO levels.10,16 Also, it has been
shown that eosinophils could be one of the sources of
the increased NO production26 and NO production
might be involved in facilitating the migration of
eosinophils.27 Taken together, it is suggested that an
ongoing recruitment and activation of inflammatory
cells may be present in the airways of some severe
Matsunaga K et al.
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asthmatic patients with sustained high FENO even
when treated by high-dose ICS. It has been reported
that most of the patients with severe asthma on
chronic oral steroid therapy required further anti-
inflammatory therapy.28,29 Interestingly, a recent
study has shown that a monoclonal antibody against
interleukin-5 (mepolizumab) reduces the number of
asthma exacerbations in patients with severe eosino-
philic asthma, and a multivariate analysis demon-
strated that the baseline blood eosinophil count is as-
sociated with the efficacy of mepolizumab.30 Indeed,
blood eosinophilia has been identified as an inde-
pendent risk factor of persistently elevated FENO in
treated asthmatics.10 Taken together, our study sug-
gested that blood eosinophils could be a predictor of
the response to systemic anti-inflammatory therapy in
severe asthmatic patients with persistent FENO eleva-
tions.
There would be some limitations in our study.
First, the sample size was relatively small. Second,
since the study subjects had severe asthma, airway
inflammation was not assessed by cellular examina-
tion. Third, we avoided the influence of the cedar pol-
len season in Japan, but perennial allergen exposure
might be a cause of sustained high FENO.2 Finally, al-
though neither the FENO levels nor lung function
showed any difference between the observation pe-
riod and the beginning of the treatment period, inade-
quate ICS therapy including poor adherence andor
poor inhaler technique could be an explanation for
sustained high FENO in some subjects.
In conclusion, our study showed that systemic ster-
oids could suppress the residual FENO elevations in
more than half of the patients with severe asthma,
and the reduction in the FENO levels was related to
improvements in asthma control and airflow limita-
tion. The FENO levels and blood eosinophil numbers
were useful predictors of patients who could be ex-
pected to show improved residual airway inflamma-
tion by treatment with systemic steroids in severe
asthma.
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